Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Catherine Waweru"'
Publikováno v:
ERJ Open Research, Vol 10, Iss 4 (2024)
Background While antibiotics are recommended for treatment of nontuberculous mycobacterial lung disease (NTMLD), the impact of early antibiotic initiation on healthcare resource utilisation is unclear. This study compared healthcare resource utilisat
Externí odkaz:
https://doaj.org/article/bb61454fd06149c9b3b3de32e389852a
Autor:
Peter Hillmen, Jing Xie, Alan S. M. Yong, Catherine Waweru, Thuy Anh Sorof, Ravi K. Goyal, Keith L. Davis
Publikováno v:
eJHaem, Vol 2, Iss 2, Pp 219-227 (2021)
Abstract Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017,
Externí odkaz:
https://doaj.org/article/64a0d007117945a597b923277fa9e33d
Publikováno v:
Open Forum Infectious Diseases. 9
Background The 2020 treatment guidelines for patients diagnosed with nontuberculous mycobacterial lung disease (NTMLD) recommend antibiotic treatment initiation rather than “watchful waiting” for most patients. Little is known regarding how delay
Autor:
Catherine Waweru, Peter Hillmen, Keith L. Davis, Ravi K. Goyal, Thuy Anh Sorof, Jing Xie, Alan S. M. Yong
Publikováno v:
eJHaem. 2:219-227
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017, represent
Publikováno v:
Current Medical Research and Opinion. 36:1481-1495
To quantify the health-related quality of life (HRQoL) and economic burden of chronic lymphocytic leukemia (CLL).Studies were searched through Embase, MEDLINE, PubMed, and Cochrane Library, as well as conference abstracts (1 January 2000-2 June 2019)
Publikováno v:
Leukemialymphoma. 62(10)
Acalabrutinib is a highly selective, potent, next-generation, covalent Bruton tyrosine kinase inhibitor with minimal off-target activity. Matching-adjusted indirect comparisons (MAICs) were performed to estimate the safety and efficacy of acalabrutin
Autor:
Sarang Abhyankar, Gautamjeet Singh, Catherine Waweru, Veronique Leblond, Amie Padhiar, Pauline Le Nouveau, Matthew S. Davids
Publikováno v:
Clinical therapeutics. 42(10)
Purpose The goal of this study was to estimate the relative efficacy of acalabrutinib (monotherapy and in combination with obinutuzumab) compared with standard frontline treatments for chronic lymphocytic leukemia (CLL) in fludarabine-ineligible pati
Publikováno v:
Blood. 136:13-14
Introduction: Acalabrutinib is a highly selective, irreversible, next-generation, Bruton tyrosine kinase inhibitor (BTKi) approved for the treatment of patients with chronic lymphocytic leukemia (CLL). Acalabrutinib and ibrutinib are the only BTKis a
Autor:
Kathleen W. Wyrwich, Claudia Wolff, Simon Eggington, Anna Steenrod, David Jay Wright, Catherine Waweru
Publikováno v:
Journal of Medical Economics. 20:732-739
Aim: To estimate health resource utilization (HRU) associated with the management of pacemaker complications in various healthcare systems. Methods: Electrophysiologists (EPs) from four geographical regions (Western Europe, Australia, Japan, and Nort
Publikováno v:
African Journal of Ecology. 54:342-348